SEC Form 4 · accession 0001209191-19-001522
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Zhen Li
Officer — Snr. VP, Chem and Non-Clin Dev
Period of report
Jan 1, 2019
Accepted (ET)
Jan 3, 2019 · 8:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 1, 2019 | A | 75,000 | $0.00 | A | 242,200 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments.